These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24632805)

  • 41. How to set up collaborations between academia and industrial biotech companies.
    Pronk JT; Lee SY; Lievense J; Pierce J; Palsson B; Uhlen M; Nielsen J
    Nat Biotechnol; 2015 Mar; 33(3):237-40. PubMed ID: 25748909
    [No Abstract]   [Full Text] [Related]  

  • 42. Doing science together: Gaining momentum from long-term explorative university-industry research programs.
    Rake B; Sengupta K; Lewin L; Sandström A; McKelvey M
    Drug Discov Today; 2023 Sep; 28(9):103687. PubMed ID: 37356615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IBM, Elsevier Science, and academic freedom.
    Bailar JC; Cicolella A; Harrison R; LaDou J; Levy BS; Rohm T; Teitelbaum DT; Wang YD; Watterson A; Yoshida F
    Int J Occup Environ Health; 2007; 13(3):312-7. PubMed ID: 17915545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The political economy of academic publishing: On the commodification of a public good.
    Puehringer S; Rath J; Griesebner T
    PLoS One; 2021; 16(6):e0253226. PubMed ID: 34138913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protecting intellectual property associated with Canadian academic clinical trials--approaches and impact.
    Ross S; Magee L; Walker M; Wood S
    Trials; 2012 Dec; 13():243. PubMed ID: 23270486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmaceutical industry, academia and patient advocacy organizations: what is the recipe for synergic (win-win-win) collaborations?
    Rose DM; Marshall R; Surber MW
    Respirology; 2015 Feb; 20(2):185-91. PubMed ID: 25580960
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Productive interactions in digital training partnerships: Lessons learned for regional development and university societal impact assessment.
    Marra M
    Eval Program Plann; 2022 Dec; 95():102173. PubMed ID: 36198227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary Care Research Team Assessment (PCRTA): development and evaluation.
    Carter YH; Shaw S; Macfarlane F
    Occas Pap R Coll Gen Pract; 2002 Feb; (81):iii-vi, 1-72. PubMed ID: 12049028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of knowledge, attitude and practice regarding intellectual property rights among dental task force attending private dental colleges in Navi Mumbai: a cross-sectional study.
    Kumar V; Aranha V; Bhanushali N; Jain R; Atre S; Singh S
    J Med Life; 2021; 14(1):93-99. PubMed ID: 33767792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A cultural change in UK universities.
    Sainsbury L
    Science; 2002 Jun; 296(5575):1929. PubMed ID: 12065804
    [No Abstract]   [Full Text] [Related]  

  • 52. Mapping International University Partnerships Identified by East African Universities as Strengthening Their Medicine, Nursing, and Public Health Programs.
    Yarmoshuk AN; Guantai AN; Mwangu M; Cole DC; Zarowsky C
    Ann Glob Health; 2016; 82(5):665-677.e2. PubMed ID: 28283117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A growing interest for intellectual property in universities.
    Karytinos A; Ingham A
    Pharm Pat Anal; 2015; 4(2):59-61. PubMed ID: 25853465
    [No Abstract]   [Full Text] [Related]  

  • 54. Perception, reality, and the political context of conflict of interest in university-industry relationships.
    Frankel MS
    Acad Med; 1996 Dec; 71(12):1297-304. PubMed ID: 9114887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Why university-industry partnerships matter.
    Boccanfuso AM
    Sci Transl Med; 2010 Sep; 2(51):51cm25. PubMed ID: 20881277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials.
    Bloom D; Beetsch J; Harker M; Hesterlee S; Moreira P; Patrick-Lake B; Selig W; Sherman J; Smith SK; Valentine JE; Roberts JN
    Ther Innov Regul Sci; 2018 Mar; 52(2):206-213. PubMed ID: 29714514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recalibrating intellectual property rights to enhance translational research collaborations.
    Bubela T; FitzGerald GA; Gold ER
    Sci Transl Med; 2012 Feb; 4(122):122cm3. PubMed ID: 22357536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. International stem cell collaboration: how disparate policies between the United States and the United Kingdom impact research.
    Luo J; Flynn JM; Solnick RE; Ecklund EH; Matthews KR
    PLoS One; 2011 Mar; 6(3):e17684. PubMed ID: 21408134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Article processing charges for open access publication-the situation for research intensive universities in the USA and Canada.
    Solomon D; Björk BC
    PeerJ; 2016; 4():e2264. PubMed ID: 27547569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey.
    Wager E; Woolley K; Adshead V; Cairns A; Fullam J; Gonzalez J; Grant T; Tortell S
    BMJ Open; 2014 Apr; 4(4):e004780. PubMed ID: 24747794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.